论文部分内容阅读
甲孕酮预防肿瘤化疗引起的食欲不振的功效近几年来已被临床医学工作者肯定 ,但在具体使用过程中给药剂量差距很大。笔者于 1998年 5月至 1999年 7月选择了 190例需接受化疗的恶性肿瘤患者 ,将其随机分成 6组 ,每组的剂量分别为 0mg/日 (对照组 )、2 0 0mg/日、40 0mg/日、6 0 0mg/日、80 0mg/日、10 0 0mg/日 ,观察 7天结束。将观察结果通过药物经济学的成本—效果分析 ,结果表明 ,40 0mg/日为其最佳剂量 ,而且不良反应轻微 ,为临床合理用药提供参考。
The efficacy of medroxyprogesterone in preventing the loss of appetite caused by cancer chemotherapy has been affirmed by clinicians in recent years, but the doses administered during the specific use process are quite different. From May 1998 to July 1999, the authors selected 190 patients with malignant tumors who needed chemotherapy. They were randomly divided into 6 groups. The doses for each group were 0 mg/day (control group) and 200 mg/day. 400 mg/day, 600 mg/day, 800 mg/day, 100 mg/day, observed at the end of 7 days. The observations were analyzed by the cost-effectiveness of pharmacoeconomics. The results showed that 400 mg/day was the best dose, and the adverse reactions were mild, which provided reference for clinical rational drug use.